Trial · NCT01694108
Outcomes25
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 25
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | All-cause Hospitalisations | 0-15 months of age | Intention-to-treat | Events | NUMBER |
| SECONDARY | Antibiotics | 0-15 months of age | Intention-to-treat | participants | NUMBER |
| SECONDARY | Atopic Dermatitis | 13 months of age | This analysis includes children with follow-up data from clinical examination or telephone interview. As opposed to the register-based primary outcome, adherence to telephone-interview and clinical examination was slightly lower than 100%. | participants | NUMBER |
| SECONDARY | Specific IgE | 13 months of age | This analysis includes children who participated with blood samples for this sub-study regarding specific IgE. | participants | NUMBER |
| SECONDARY | Standardized Weight at 13 Months | 13 months of age | This analysis only includes children with available follow-up data from telephone interviews or clinical examinations. As opposed to the primary outcome, follow-up was lower than 100%. | Weight z-score at 13 months | MEAN |
| SECONDARY | Psychomotor Development in Premature Infants | 13 months of age | This analysis only includes children from a particular subgroup (premature children, N = 144), who had with available follow-up data. As opposed to the primary outcome, follow-up was lower than 100%. | Score on ASQ scale | MEAN |
| SECONDARY | DTaP-IPV-Hib Vaccination Coverage at 12 Months of Age | 13 months of age | Per-protocol analysis excluding 11 children randomised to BCG who did not receive the vaccine, and 36 children randomised to control who received the BCG vaccine. | participants | NUMBER |
| SECONDARY | Standardized Weight, Length and Head Circumference of Premature Children at 13 Months | 13 months of age | Premature children born with gestational age 32-36 weeks. This analysis only includes children from a particular subgroup (premature children, N = 144), who had with available follow-up data. As opposed to the primary outcome, follow-up was lower than 100%. | z-score | MEAN |
| SECONDARY | Episodic Viral Wheeze | 13 months | This analysis only includes children with available follow-up telephone interview data. As opposed to the primary outcome, follow-up was lower than 100%. | participants | NUMBER |
| SECONDARY | Food Allergy | 13 months | This analysis only includes children with available follow-up telephone interview data. As opposed to the primary outcome, follow-up was lower than 100%. | participants | NUMBER |
| SECONDARY | Length at 13 Months of Age | 13months | This analysis only includes children with available follow-up data. As opposed to the primary outcome, follow-up for this outcome was lower than 100%. | Length z-score | MEAN |
| SECONDARY | Standardized Head Circumference at 13 Months of Age | 13 months | This analysis only includes children with available follow-up data. As opposed to the primary outcome, follow-up for this outcome was lower than 100%. | Head circumference z-score | MEAN |
| SECONDARY | Thymic Gland Size at 3 Months of Age | 3 months of age | This outcome was a sub-study to The Danish Calmette Study with 301 (BCG 153, Control 148) participating children. | Thymic index | MEAN |
| SECONDARY | Leucocyte Count 4 Days After Randomisation/Vaccination | 4 days after randomisation/vaccination within 7 days after birth | This was a sub study among 153 children with blood-samples at 4 days after randomisation/vaccination. | cell concentrations (GM*10^9 cells/L) | GEOMETRIC_MEAN |
| SECONDARY | Monocyte Count 4 Days After Randomisation/Vaccination | 4 days after randomisation/vaccination within 7 days after birth | This was a sub study among 153 children with blood-samples at 4 days after randomisation/vaccination. | Cell concentrations (GM*10^9 cells/L) | GEOMETRIC_MEAN |
| SECONDARY | Interferon Gamma Response | 13 months of age | This is a sub study using bloodsamples. Only a small sub population from the overall trial participated. | participants | NUMBER |
| SECONDARY | Number of Participants With Antibody Concentration (AC) Against Tetanus of > 0.1 IU/mL | 13 months of age | This outcome was a sub-study with 158 participants. Antibody concentration (AC) of \> 0.1 IU/mL was considered protective | participants | NUMBER |
| SECONDARY | Number of Events of Common Cold | 13 months of age | This analysis only includes children with available follow-up data. As opposed to the primary outcome, follow-up for this outcome was lower than 100%. | Events | NUMBER |
| SECONDARY | Number of Events of Pneumonia | 13 months of age | This analysis only includes children with available follow-up data. As opposed to the primary outcome, follow-up for this outcome was lower than 100%. | Events | NUMBER |
| SECONDARY | Number of Events of Febrile Episodes | 13 months of age | This analysis only includes children with available follow-up data. As opposed to the primary outcome, follow-up for this outcome was lower than 100%. | Events | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01694108/outcomes